EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway

Naser-Aldin Lashgari iD, Danial Khayatan iD, Nazanin Momeni Roudsari iD, Saeideh Momtaz iD, Ahmad Reza Dehpour, Amir Hossein Abdolghaffari iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-03 · 397 (3) · 1433-1454

DOI: 10.1007/s00210-023-02684-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 22.09.2023. Verfasst von Naser-Aldin Lashgari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati S…. Hauptthemen laut MEDLINE: Cholestasis, Liver Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 110 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholestasis describes bile secretion or flow impairment, which is clinically manifested with fatigue, pruritus, and jaundice. Neutrophils play a crucial role in many diseases such as cholestasis liver diseases through mediating several oxidative and inflammatory pathways. Data have been collected from clinical, in vitro, and in vivo studies published between 2000 and December 2021 in English and obtained from the PubMed, Google Scholar, Scopus, and Cochrane libraries. Although nitric oxide plays an important role in the pathogenesis of cholestatic liver diseases, excessive levels of NO in serum and affected tissues, mainly synthesized by the inducible nitric oxide synthase (iNOS) enzyme, can exacerbate inflammation. NO induces the inflammatory and oxidative processes, which finally leads to cell damage. We found that natural products such as baicalin, curcumin, resveratrol, and lycopene, as well as chemical likes ursodeoxycholic acid, dexamethasone, rosuvastatin, melatonin, and sildenafil, are able to markedly attenuate the NO production and iNOS expression, mainly through inducing the nuclear factor κB (NF-κB), Janus kinase and signal transducer and activator of transcription (JAK/STAT), and toll like receptor-4 (TLR4) signaling pathways. This study summarizes the latest scientific data about the bile acid signaling pathway, the neutrophil chemotaxis recruitment process during cholestasis, and the role of NO in cholestasis liver diseases. Literature review directed us to propose that suppression of NO and its related pathways could be a therapeutic option for preventing or treating cholestatic liver diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisLiver DiseasesHumansNitric OxideSignal TransductionNF-kappa BNitric Oxide Synthase Type IILiver

Stichwörter der Autor:innen

CholestasisInflammationLiver diseasesNitric oxideOxidative stress

Substanzen

Nitric OxideNF-kappa BNitric Oxide Synthase Type II

Autor:innen und Institutionen

  • Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran, Iran, P. O. Box: 19419-33111.
  • GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  • Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran.
  • Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com.
  • Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com.

ORCID-Profile: Naser-Aldin Lashgari, Danial Khayatan, Nazanin Momeni Roudsari, Saeideh Momtaz, Amir Hossein Abdolghaffari

Zitieren

APA

Lashgari, N. A., Khayatan, D., Roudsari, N. M., Momtaz, S., Dehpour, A. R., & Abdolghaffari, A. H. (2024). Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(3), 1433-1454. https://doi.org/10.1007/s00210-023-02684-2

Vancouver

Lashgari NA, Khayatan D, Roudsari NM, Momtaz S, Dehpour AR, Abdolghaffari AH. Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(3):1433-1454. doi:10.1007/s00210-023-02684-2

BibTeX
@article{Lashgari2024,
  author = {Lashgari, Naser-Aldin and Khayatan, Danial and Roudsari, Nazanin Momeni and Momtaz, Saeideh and Dehpour, Ahmad Reza and Abdolghaffari, Amir Hossein},
  title = {Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  volume = {397},
  number = {3},
  pages = {1433--1454},
  doi = {10.1007/s00210-023-02684-2}
}
Kostenlos starten →